Last reviewed · How we verify
NCT07439341
AGE and CALLY Index in Familial Mediterranean Fever
trial testing Skin Autofluorescence Measurement in Familial Mediterranean Fever in 150 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | Bursa City Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 February 2026 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 November 2026 |
Drugs / interventions tested
- Skin Autofluorescence Measurement
Conditions studied
- Familial Mediterranean Fever — all drugs for Familial Mediterranean Fever →
Sponsor
Bursa City Hospital
Who can join
Adults 18 to 65, any sex, with Familial Mediterranean Fever. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation. Even during attack-free periods, subclinical inflammation may continue and contribute to long-term complications. Advanced glycation end products (AGEs) are molecules that accumulate under chronic inflammatory and oxidative stress conditions. AGEs can be measured non-invasively using skin autofluorescence (SAF). The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite marker derived from routine laboratory parameters and reflects systemic inflammation and nutritional status. This observational cross-sectional study aims to evaluate the association between skin autofluorescence-measured AGE levels and the CALLY index in patients with FMF. The study will also compare AGE levels between FMF patients and age- and sex-matched healthy controls. The study does not involve any intervention, treatment assignment, or randomization. All laboratory parameters will be obtained from routine clinical evaluations, and AGE measurement will be performed using a non-invasive device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07439341
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Familial Mediterranean Fever
Currently open trials in the same condition.
- NCT07129538 — Outcomes of Inspiratory Muscle Training in FMF Adolescents · NA · recruiting
- NCT07130305 — is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT07128225 — Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever · active not recruiting
- NCT06338891 — Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks · recruiting
Other Bursa City Hospital trials
Trials by the same sponsor.
- NCT06925256 — Considering Peripheral Nerve Injury, Is It Safe to Perform Transradial Angiography? · NA · not yet recruiting
- NCT07480278 — mTLIP vs QIPB for Postoperative Analgesia in Lumbar Microdiscectomy Surgery · NA · recruiting
- NCT07482345 — Impact of Different Fasting Strategies on Gastric Ultrasound and Anxiety Levels in Children · NA · not yet recruiting
- NCT07370415 — mTLIP vs QIPB for Postoperative Analgesia After Lumbar Instrumentation Surgery · NA · not yet recruiting
- NCT07410000 — Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07439341 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bursa City Hospital
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07439341.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing